
According to Benzinga Pro data, during Q1, Akebia Therapeutics (NASDAQ:AKBA) posted sales of $61.70 million. Earnings were up 11.68%, but Akebia Therapeutics still reported an overall loss of $62.42 million. In Q4, Akebia Therapeutics brought in $59.60 million in sales but lost $70.68 million in earnings.